Circulating 27-hydroxycholesterol and breast cancer tissue expression of CYP27A1, CYP7B1, LXR-β, and ERβ: results from the EPIC-Heidelberg cohort

被引:23
作者
Le Cornet, Charlotte [1 ]
Walter, Britta [2 ]
Sookthai, Disorn [1 ]
Johnson, Theron S. [1 ]
Kuehn, Tilman [1 ]
Herpel, Ester [2 ,3 ]
Kaaks, Rudolf [1 ]
Fortner, Renee T. [1 ]
机构
[1] German Canc Res Ctr, Div Canc Epidemiol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany
[2] Univ Hosp Heidelberg, Inst Pathol, Neuenheimer Feld 224, D-69120 Heidelberg, Germany
[3] Natl Ctr Tumor Dis NCT, Tissue Bank, Neuenheimer Feld 460, D-69120 Heidelberg, Germany
关键词
27-hydroxycholeterol; Tissue microarray; Immunohistochemistry; Cholesterol metabolism; Breast cancer; ESTROGEN-RECEPTOR-BETA; PROGNOSTIC MARKER; PROSTATE-CANCER; RISK; OVEREXPRESSION; PROLIFERATION; CHOLESTEROL; REGULATOR; THERAPY; BCL2;
D O I
10.1186/s13058-020-1253-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Experimental and epidemiological studies demonstrate a role for 27-hydroxycholesterol (27HC) in breast cancer development, though results are conflicting. Cholesterol 27-hydroxylase (CYP27A1) and oxysterol 7-alpha-hydroxylase (CYP7B1) regulate 27HC concentrations, while differential expression of the liver X receptor (LXR) and estrogen receptor beta (ER beta) may impact the association between 27HC and breast cancer risk. Methods We evaluated correlates of tumor tissue expression of CYP27A1, CYP7B1, LXR-beta, and ER beta and the association between circulating prediagnostic 27HC concentrations and breast cancer risk by marker expression in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC)-Heidelberg cohort including 287 breast cancer cases with tumor tissue available. Tumor protein expression was evaluated using immunohistochemistry, and serum 27HC concentrations quantified using liquid chromatography-mass spectrometry. Conditional logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). Results A higher proportion of CYP7B1-positive cases were progesterone receptor (PR)-positive, relative to CYP7B1-negative cases, whereas a higher proportion of ER beta-positive cases were Bcl-2 low, relative to ER beta-negative cases. No differences in tumor tissue marker positivity were observed by reproductive and lifestyle factors. We observed limited evidence of heterogeneity in associations between circulating 27HC and breast cancer risk by tumor tissue expression of CYP27A1, CYP7B1, LXR-beta, and ER beta, with the exception of statistically significant heterogeneity by LXR-beta status in the subgroup of women perimenopausal at blood collection (p = 0.02). Conclusion This exploratory study suggests limited associations between tumor marker status and epidemiologic or breast cancer characteristics. Furthermore, the association between circulating 27HC and breast cancer risk may not vary by tumor expression of CYP27A1, CYP7B1, LXR-beta, or ER beta.
引用
收藏
页数:10
相关论文
共 43 条
  • [1] Statins and breast cancer prognosis: evidence and opportunities
    Ahern, Thomas P.
    Lash, Timothy L.
    Damkier, Per
    Christiansen, Peer M.
    Cronin-Fenton, Deirdre P.
    [J]. LANCET ONCOLOGY, 2014, 15 (10) : E461 - E468
  • [2] The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells
    Baek, Amy E.
    Yu, Yen-Rei A.
    He, Sisi
    Wardell, Suzanne E.
    Chang, Ching-Yi
    Kwon, Sanghoon
    Pillai, Ruchita V.
    McDowell, Hannah B.
    Thompson, J. Will
    Dubois, Laura G.
    Sullivan, Patrick M.
    Kemper, Jongsook K.
    Gunn, Michael D.
    McDonnell, Donald P.
    Nelson, Erik R.
    [J]. NATURE COMMUNICATIONS, 2017, 8
  • [3] EPIC-Germany - A source for studies into diet and risk of chronic diseases
    Boeing, H
    Wahrendorf, J
    Becker, N
    [J]. ANNALS OF NUTRITION AND METABOLISM, 1999, 43 (04) : 195 - 204
  • [4] Statin Use and Breast Cancer Risk in the Nurses' Health Study
    Borgquist, Signe
    Tamimi, Rulla M.
    Chen, Wendy Y.
    Garber, Judy E.
    Eliassen, A. Heather
    Ahern, Thomas P.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2016, 25 (01) : 201 - 206
  • [5] Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index
    Callagy, GM
    Pharoah, PD
    Pinder, SE
    Hsu, FD
    Nielsen, TO
    Ragaz, J
    Ellis, IO
    Huntsman, D
    Caldas, C
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (08) : 2468 - 2475
  • [6] Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study
    Dalenc, Florence
    Iuliano, Luiggi
    Filleron, Thomas
    Zerbinati, Chiara
    Voisin, Maud
    Arellano, Cecile
    Chatelut, Etienne
    Marquet, Pierre
    Samadi, Mohammad
    Roche, Henri
    Poirot, Marc
    Silvente-Poirot, Sandrine
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2017, 169 : 210 - 218
  • [7] BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received
    Dawson, S-J
    Makretsov, N.
    Blows, F. M.
    Driver, K. E.
    Provenzano, E.
    Le Quesne, J.
    Baglietto, L.
    Severi, G.
    Giles, G. G.
    McLean, C. A.
    Callagy, G.
    Green, A. R.
    Ellis, I.
    Gelmon, K.
    Turashvili, G.
    Leung, S.
    Aparicio, S.
    Huntsman, D.
    Caldas, C.
    Pharoah, P.
    [J]. BRITISH JOURNAL OF CANCER, 2010, 103 (05) : 668 - 675
  • [8] 27-Hydroxycholesterol: a potential endogenous regulator of estrogen receptor signaling
    DuSell, Carolyn D.
    McDonnell, Donald P.
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2008, 29 (10) : 510 - 514
  • [9] The Endogenous Selective Estrogen Receptor Modulator 27-Hydroxycholesterol Is a Negative Regulator of Bone Homeostasis
    DuSell, Carolyn D.
    Nelson, Erik R.
    Wang, Xiaojuan
    Abdo, Jennifer
    Moedder, Ulrike I.
    Umetani, Michihisa
    Gesty-Palmer, Diane
    Javitt, Norman B.
    Khosla, Sundeep
    McDonnell, Donald P.
    [J]. ENDOCRINOLOGY, 2010, 151 (08) : 3675 - 3685
  • [10] El Roz A, 2012, ANTICANCER RES, V32, P3007